

Author: Page Clive Spina Domenico
Publisher: Humana Press, Inc
ISSN: 1080-0549
Source: Clinical Reviews in Allergy and Immunology, Vol.31, Iss.2-3, 2006-06, pp. : 143-161
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Bronchial hyperresponsiveness (BHR) is a characteristic feature of asthma, and individuals with this disease respond to a range of physiological and chemical insults that are otherwise innocuous to healthy subjects, suggesting that the mechanisms underlying this phenomenon are characteristic of the asthma phenotype. BHR can be increased following exposure to environmental allergens in suitably sensitized individuals, pollutants, and certain viruses and can also be exacerbated by exposure to certain drugs, including nonsteroidal anti-inflammatory agents and β-blockers. Although β2-agonists administered acutely remain the treatment for the symptoms of asthma, paradoxically, regular treatment with these drugs can result in an increase in BHR, and this has been suggested to contribute to the increase in asthma morbidity and mortality that has been reported by numerous investigators. This article highlights our current understanding of this phenomenon and examines the potential mechanisms responsible for this effect.
Related content


Clinical Reviews in Allergy and Immunology, Vol. 31, Iss. 2-3, 2006-06 ,pp. :


β2-Agonists at the olympic games
Clinical Reviews in Allergy and Immunology, Vol. 31, Iss. 2-3, 2006-06 ,pp. :


Interactions between corticosteroids and β2-agonists
Clinical Reviews in Allergy and Immunology, Vol. 31, Iss. 2-3, 2006-06 ,pp. :


β2-Agonists and exercise-induced asthma
By Anderson Sandra Caillaud Corinne Brannan John
Clinical Reviews in Allergy and Immunology, Vol. 31, Iss. 2-3, 2006-06 ,pp. :


β2-Agonists for asthma: The pediatric perspective
By Subbarao Padmaja Ratjen Felix
Clinical Reviews in Allergy and Immunology, Vol. 31, Iss. 2-3, 2006-06 ,pp. :